28 clinical trials matched your search for Prostate Cancer. You can click one of the clinical trials below for more information, or click the Search Again button to enter different search text.

Search Again
Condition Study Title Investigator
Prostate Cancer IRONMAN: International Registry for Men with Advanced Prostate Cancer Mark Stein, MD
Prostate Cancer Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer Mark Stein, MD
Prostate Cancer Study of XmAb20717 Alone or in Combination with Chemotherapy in Patients with Prostate Cancer Mark Stein, MD
Prostate Cancer Study of CC-94676 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Karie D. Runcie, MD
Prostate Cancer Study of JNJ-78278343 in Patients with Advanced Prostate Cancer Mark Stein, MD
Prostate Cancer Study of Whole-Food Plant-Based Diet (WFPBD) to Control Weight in Overweight/Obese Men with Prostate Cancer Mark Stein, MD
Prostate Cancer Study of VTP-850 in Male Patients with Prostate Cancer Whose Prostate-Specific Antigen (PSA) Levels Have Risen Mark Stein, MD
Prostate Cancer Study of JNJ-87189401 in Combination with JNJ 78278343 in Patients with Prostate Cancer Mark Stein, MD
Prostate Cancer Study of Apalutamide Alone or in Combination with ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Karie D. Runcie, MD
Prostate Cancer Study of ONC-392 in Combination with PLUVICTO in Male Patients with Prostate Cancer Mark Stein, MD
Cancer Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Mark Stein, MD
Cancer Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) Brian Henick, MD
Cancer Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Catherine Shu, MD
Cancer Study of Financial Navigator Addressing Cancer-Related Financial Hardship in Cancer Patients and Their Spouses Dawn Hershman, MD
Cancer Study of RP-3500 in Combination with PARP Inhibitor for Patients with Advanced Cancer Benjamin Herzberg, MD
Cancer Study of IDE397 in Patients with Advanced Solid Tumors Benjamin Herzberg, MD
Cancer Study of CS5001 in Patients with Advanced Solid Tumors Hua-Jay Cherng, MD
Cancer Study of ASP3082 in Patients with Advanced Cancer with a KRAS G12D Mutation Benjamin Herzberg, MD
Cancer Study of 68Ga-FAP-2286 and 177Lu-FAP-2286 in Patients with Advanced Cancer Ryan Moy, MD
Cancer Study of BLU-222 Alone or in Combination with Other Cancer Therapy for Patients with Advanced Cancer Brian Henick, MD
Cancer Study of LNS8801 Alone or in Combination with Pembrolizumab in Patients with Advanced Cancer Brian Henick, MD
Cancer Study of RMC-6291 in Patients with Advanced Solid Tumors Benjamin Herzberg, MD
Cancer Study of XL092 Alone or in Combination with Anticancer Therapy in Patients with Unresectable orMetastatic Solid Tumors Karie D. Runcie, MD
Cancer Study of MRT-2359 in Patients with Solid Tumors Benjamin Herzberg, MD
Cancer Study of RMC-6236 in Patients with Solid Tumors with a KRAS Mutation Benjamin Herzberg, MD
Cancer Study of NDI-101150 Alone or in Combination with Pembrolizumab in Patients with Solid Tumors Ryan Moy, MD
Cancer Study of XmAb808 in Combination with Pembrolizumab in Patients with Advanced Cancer Mark Stein, MD
Cancer Study of HRO761 Alone or in Combination with Tislelizumab or Irinotecan in Patients with Solid Tumors Edmond Chan, MD
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE